Group of Patients in Clinical Trial with Cellect's ApoGraft Stem Cell Transplant Follow up Results

Group of Patients in Clinical Trial with Cellect's ApoGraft Stem Cell Transplant Follow up Results

Zero Related Adverse Events

Yarkoni, Cellect CEO commented:

interim results further support that we are closer than ever to a world where stem cells are used to replace sick organs and damaged

technology, ApoGraft , aims to become a game changer

cell use for regenerative medicine

Israel - January 4, 2018 - Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell selection technology,

announced that it has successfully completed transplantation of the first group of three patients using Cellect's ApoGraft

technology in the Company's Phase I/II clinical trial and that after one month follow-up, all three patients have demonstrated

complete acceptance of the stem cell transplant with no adverse events related to the study treatment, as determined by the clinical

investigator, and no reported serious adverse events or suspected unexpected serious adverse reactions.

I/II, dose escalating, 4-cohort, open label clinical trial of up to twelve patients is designed to evaluate the safety, tolerability

and efficacy of functionally selected donor derived mobilized peripheral blood cells that underwent the Company's ApoGraft

process and were transplanted into patients with hematological malignancies in an allogeneic hematopoietic stem cell transplantation.

The primary endpoint of the study is overall incidence, frequency and severity of adverse events potentially related to Apograft

at 180 days from transplantation. The Company plans on recruiting a further three patients for the second cohort of patients following

review of the independent data and safety monitoring board.

believes that these interim results of ApoGraft present the first signs of a breakthrough in stem cell transplantation. The product

is transplantable within less than 12 hours from donation through a simple process performed on the bedside after selective physiological

elimination of immune reaction-causing cells. The ApoGraft transplantation is intended to result in complete recovery of the patient's

immune system with no related safety concerns in contrast to the significant morbidity or even death causing standard medical

Yarkoni, Cellect's CEO said, "Our ApoGraft technology shows consistently successful results in the use of stem

cell transplants for treating patients suffering from life-threatening conditions. We see our position strengthened with each

patient treated. We aim for stem cell based regenerative medicine to become a safe and affordable treatment for most of mankind's

are the building blocks and raw material of 21st century regenerative medicine enabling a world where damaged tissues

and organs may be replaced and regenerated rather than fixed with drugs, radiation and surgery. However, up to 50 percent of stem

cell transplant procedures, such as bone marrow transplants and others, result in life-threatening rejection disease and other

immune responses such as Graft-versus-Host-Disease (GvHD). Cellect's ApoGraft technology aims to turn stem cell transplantations

into a simple and safe, yet cost effective procedure by reducing the associated severe side effects, such as rejection and many

improved prophylactic regimens, acute GvHD disease still occurs in an estimated 25% to 50% of recipients of allogeneic stem cell

transplantation. The incidence of acute or chronic GvHD in these patients is increasing due to the increased number of allogeneic

transplantations survivors, older recipient age, use of alternative donor grafts and use of peripheral blood as the source of

stem cells. GvHD accounts for an estimated 15% of deaths and is considered the leading cause of non-relapse mortality after allogeneic

bone marrow transplantation.

About Cellect Biotechnology

Biotechnology (NASDAQ: APOP) has developed a breakthrough technology for the selection of stem cells from any given tissue that

aims to improve a variety of stem cell-based therapies.

technology is expected to provide research, hospitals and pharma companies with the tools to rapidly isolate stem cells in quantity

and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The

current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements

can be identified by the use of forward-looking words such as "believe", "expect", "intend",

"plan", "may", "should", "could", "might", "seek", "target",

"will", "project", "forecast", "continue" or "anticipate" or their

negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to

historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's aim

at making its ApoGraft technology a game changer in stem cell transplantations, Cellect's intent regarding the effects

of the Apograft transplantation, Cellect's expectations regarding the implications of the results reported in this

press release, and Cellect's aims and expectations regarding the future of its Apograft technology and stem cell

based regenerative medicine. These forward-looking statements and their implications are based on the current expectations of

the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results to

differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from

procedures, scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or

that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following

factors, among others, could cause actual results to differ materially from those described in the forward-looking statements:

changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing

our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress

further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose

knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our

products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results

in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents

may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new

technologies, products and applications, which could cause the actual results or performance of the Company to differ materially

from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as

of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement,

whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities

laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk

Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2016 filed with

the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov. and in the Company's

period filings with the SEC.

Cellect Biotechnology Ltd.

Eyal Leibovitz, Chief Financial